CLINICAL AND IMMUNOLOGICAL EFFICIENCY OF MURAMYLDIPEPTIDE GROUP MEDICINE IN A THERAPY OF SCARLET FEVER THERAPY IN CHILDREN
Abstract
Aim. To assess the clinical-immunological effectiveness of Lycopid medicine in the treatment of scarlet fever in children.
Material and methods. 78 patients with moderate and severe forms of scarlet fever aged 2 to 14 years were under the observation. Depending on the nature of the therapy, children have divided into two groups: the main-group, in addition to the basic-therapy, received the immunomodulator Lycopid, and the control group received only the basic-therapy.
Results and discussion. The results of clinical studies have shown that the inclusion of Lcopid to the complex therapy of patients of the main-group, accelerated the clinical recovery. There was a significant reduction of intoxication symptoms duration and a local inflammatory process in the throat of the main-group patients compared to the control group (p <0.001). Also, the use of an immunomodulator in the complex therapy of scarlet fever significantly faster led to the normalization of cellular and humoral immunity indicators in patients of the main-group.
Conclusion. The clinical and immunological efficacy of the use of the Lycopid immunomodulator in the treatment of patients with scarlet fever has been established. It indicates the feasibility of using the drug in the treatment of scarlet fever in children.
About the Authors
N. M. Khodzhaeva
SEI Avicenna Tajik State Medical University
Tajikistan
Tajikistan
Khodjaeva Nigina Murodovna - Doctor of Medical Sciences, Professor of the Department of Pediatric Infectious Diseases
Z. R. Boboeva
SEI Avicenna Tajik State Medical University
Tajikistan
Tajikistan
Department of Pediatric Infectious Diseases
M. S. Fuzaylova
SEI Avicenna Tajik State Medical University
Tajikistan
Tajikistan
Department of Pediatric Infectious Diseases
References
1. Abdullaeva N. A. Kliniko-immunologicheskie osobennosti techeniya pnevmoniy u detey rannego vozrasta [Clinical and immunological features of the course of pneumonia in young children]. Zdravookhranenie Tadzhikistana – Healthcare of Tajikistan, 2014, No. 1, pp. 37-41.
2. Belov B. S. A-streptokokkovaya infektsiya na rubezhe vekov [A - streptococcal infection at the turn of the century]. Nauchno-prakticheskaya revmatologiya - Scientific and practical rheumatology, 2002, No. 1, pp. 29-34.
3. Krasnova E. I. Streptokokkovaya infektsiya. Monografiya [Streptococcal infection. Monograph]. Novosibirsk, Sibmedizdatelsvo NGMU Publ., 2015. 160 p.
4. Levanovich V. V. Evolyutsiya streptokokkovoy infektsii. Rukovodstvo dlya vrachey [Evolution of streptococcal infection. A guide for doctors]. St. Petersburg, Spetslit Publ., 2015. 495 p.
Review
For citations:
Khodzhaeva N.M., Boboeva Z.R., Fuzaylova M.S. CLINICAL AND IMMUNOLOGICAL EFFICIENCY OF MURAMYLDIPEPTIDE GROUP MEDICINE IN A THERAPY OF SCARLET FEVER THERAPY IN CHILDREN. Health care of Tajikistan. 2020;(3):63-68. (In Russ.)
Views:
279
Email this article 